Recurrent Plaque Morphea Successfully Treated with PDO Mono Threads and Topical Tacrolimus Ointment

Overview

Journal J Clin Aesthet Dermatol

Date 2021 Feb 15

PMID 33584956

Authors

Jagdish Sakhiya

Dhruv Sakhiya

Ashish Dedakiya

Madhav Purohit

Mihir Modi

Piyush Darji

Feral Daruwala

Nimish Dudhatra

Affiliations

Soon will be listed here.

Abstract

The term describes a variant of morphea (localized scleroderma) in which oval or round circumscribed areas of induration, pigmentary changes, and violaceous or erythematous halo (i.e., lilac ring) are found in the dermis and occasionally to the superficial panniculus. We report a case of 28-year-old male patient with recurrent plaque morphea who was treated with polydioxanone (PDO) mono threads and topical tacrolimus ointment. After the introduction of PDO mono threads, the patient was prescribed topical tacrolimus ointment for six months. After that six-month period, the lesions were softer to palpation and lighter in color. This was observed as a positive therapeutic response. Notably, no future recurrence was seen at one-year follow up.

References

Badea I, Taylor M, Rosenberg A, Foldvari M . Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis. Rheumatology (Oxford). 2008; 48(3):213-21. DOI: 10.1093/rheumatology/ken405. View

Zulian F . Systemic manifestations in localized scleroderma. Curr Rheumatol Rep. 2004; 6(6):417-24. DOI: 10.1007/s11926-004-0020-5. View

Savoia P, Zaccagna A, Bernengo M . Guess what? Inflammatory disseminated morphea profunda. Eur J Dermatol. 2000; 9(8):654-6. View

Laxer R, Zulian F . Localized scleroderma. Curr Opin Rheumatol. 2006; 18(6):606-13. DOI: 10.1097/01.bor.0000245727.40630.c3. View

Fett N, Werth V . Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2011; 64(2):217-28. DOI: 10.1016/j.jaad.2010.05.045. View

CUNNINGHAM B, Landells I, Langman C, Sailer D, Paller A . Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol. 1998; 39(2 Pt 1):211-5. DOI: 10.1016/s0190-9622(98)70077-5. View

Grabell D, Hsieh C, Andrew R, Martires K, Kim A, Vasquez R . The role of skin trauma in the distribution of morphea lesions: a cross-sectional survey of the Morphea in Adults and Children cohort IV. J Am Acad Dermatol. 2014; 71(3):493-8. PMC: 4135004. DOI: 10.1016/j.jaad.2014.04.009. View

Leitenberger J, Cayce R, Haley R, Adams-Huet B, Bergstresser P, Jacobe H . Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol. 2009; 145(5):545-50. PMC: 2938024. DOI: 10.1001/archdermatol.2009.79. View

Dytoc M, Ting P, Man J, Sawyer D, Fiorillo L . First case series on the use of imiquimod for morphoea. Br J Dermatol. 2005; 153(4):815-20. DOI: 10.1111/j.1365-2133.2005.06776.x. View

10.

Peterson L, Nelson A, Su W . Classification of morphea (localized scleroderma). Mayo Clin Proc. 1995; 70(11):1068-76. DOI: 10.4065/70.11.1068. View

11.

Chung L, Lin J, Furst D, Fiorentino D . Systemic and localized scleroderma. Clin Dermatol. 2006; 24(5):374-92. DOI: 10.1016/j.clindermatol.2006.07.004. View

12.

Dytoc M, Kossintseva I, Ting P . First case series on the use of calcipotriol-betamethasone dipropionate for morphoea. Br J Dermatol. 2007; 157(3):615-8. DOI: 10.1111/j.1365-2133.2007.07971.x. View

13.

Kroft E, Groeneveld T, Seyger M, de Jong E . Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol. 2009; 10(3):181-7. DOI: 10.2165/00128071-200910030-00004. View

14.

Omair M, Johnson S . Inflammatory arthritis, sacroiliitis, and morphea: evidence of a systemic inflammatory disease. Case Rep Rheumatol. 2013; 2013:347694. PMC: 3749611. DOI: 10.1155/2013/347694. View

15.

Batchelor R, Lamb S, Goulden V, Stables G, Goodfield M, Merchant W . Photodynamic therapy for the treatment of morphoea. Clin Exp Dermatol. 2008; 33(5):661-3. DOI: 10.1111/j.1365-2230.2008.02873.x. View